Bugelski PJ[au] - Search Results

Year	Number of Results
1981	1
1983	1
1985	3
1987	5
1988	3
1989	6
1990	6
1991	7
1992	5
1993	6
1994	4
1995	7
1996	2
1997	2
1998	1
1999	3
2000	4
2001	5
2002	3
2003	1
2004	1
2005	3
2006	1
2007	7
2008	5
2009	3
2010	5
2011	3
2012	3
2013	1
2022	0

1

A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells.

LaBranche CC, Sauter MM, Haggarty BS, Vance PJ, Romano J, Hart TK, Bugelski PJ, Marsh M, Hoxie JA. LaBranche CC, et al. Among authors: bugelski pj. J Virol. 1995 Sep;69(9):5217-27. doi: 10.1128/JVI.69.9.5217-5227.1995. J Virol. 1995. PMID: 7636963 Free PMC article.

2

Monoclonal antibody-induced cytokine-release syndrome.

Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Bugelski PJ, et al. Expert Rev Clin Immunol. 2009 Sep;5(5):499-521. doi: 10.1586/eci.09.31. Expert Rev Clin Immunol. 2009. PMID: 20477639

3

Genetic aspects of immune-mediated adverse drug effects.

Bugelski PJ. Bugelski PJ. Nat Rev Drug Discov. 2005 Jan;4(1):59-69. doi: 10.1038/nrd1605. Nat Rev Drug Discov. 2005. PMID: 15688073 Review.

4

B cells and beyond: therapeutic opportunities targeting inflammation.

Liang B, Eaton-Bassiri A, Bugelski PJ. Liang B, et al. Among authors: bugelski pj. Inflamm Allergy Drug Targets. 2007 Sep;6(3):142-9. doi: 10.2174/187152807781696473. Inflamm Allergy Drug Targets. 2007. PMID: 17897050 Review.

5

Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome.

Walker M, Makropoulos D, Achuthanandam R, Bugelski PJ. Walker M, et al. Among authors: bugelski pj. Curr Opin Drug Discov Devel. 2010 Jan;13(1):124-35. Curr Opin Drug Discov Devel. 2010. PMID: 20047153 Review.

6

Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.

Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, Descotes J. Bugelski PJ, et al. Int J Toxicol. 2010 Sep-Oct;29(5):435-66. doi: 10.1177/1091581810374654. Int J Toxicol. 2010. PMID: 20884856 Review.

7

Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Martin PL, Bugelski PJ. Martin PL, et al. Among authors: bugelski pj. Br J Pharmacol. 2012 Jun;166(3):806-22. doi: 10.1111/j.1476-5381.2011.01812.x. Br J Pharmacol. 2012. PMID: 22168335 Free PMC article. Review.

8

Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Bugelski PJ, Martin PL. Bugelski PJ, et al. Br J Pharmacol. 2012 Jun;166(3):823-46. doi: 10.1111/j.1476-5381.2011.01811.x. Br J Pharmacol. 2012. PMID: 22168282 Free PMC article. Review.

9

Drug delivery to macrophages for the therapy of cancer and infectious diseases.

Kirsh R, Bugelski PJ, Poste G. Kirsh R, et al. Among authors: bugelski pj. Ann N Y Acad Sci. 1987;507:141-54. doi: 10.1111/j.1749-6632.1987.tb45797.x. Ann N Y Acad Sci. 1987. PMID: 3327409 Review.

10

HIV protease inhibitors: effects on viral maturation and physiologic function in macrophages.

Bugelski PJ, Kirsh R, Hart TK. Bugelski PJ, et al. J Leukoc Biol. 1994 Sep;56(3):374-80. doi: 10.1002/jlb.56.3.374. J Leukoc Biol. 1994. PMID: 8083611 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results